Botanical species · safety record

Coptis chinensis

The EFSA Compendium of Botanicals holds 29 constituent measurements, 8 adverse-effect records and 1 genotoxicity assay for Coptis chinensis. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Coptis chinensis Franch.

29Constituent measurements
9Safety records
8Cited sources
656Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 656 licensed products naming Coptis chinensis as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

  • Dry
  • Extract Type TBA
  • decoction
  • solid

Source material stated

  • Coptis chinensis - Rhizome
  • Coptis deltoidea - Rhizome
  • Coptis teeta - Rhizome
  • Dried rhizome
  • Rhizome
  • Rhizome (dry-fried)
  • Rhizome (stir-baked with ginger juice)
  • Rhizome (stir-baked with wine)

What the records describe

Constituents measured

  • Berberine4
  • Coptisine4
  • Alkaloids3
  • Jatrorrhizine3
  • Palmatine3
  • Berberrubine2
  • Columbamine2
  • Epiberberine2
  • Magnoflorine2
  • Noroxyhydrastinine2

Plant parts

  • Roots and other underground parts27
  • Unspecified7
  • Flower2

Preparations

  • Solvent extraction31
  • Raw, no heat treatment2

Effect types

  • Digestive2
  • Hepatotoxicity2
  • Systemic2
  • Endocrine1
  • Nephrotoxicity1

Target tissues

  • Digestive4
  • Liver2
  • Heart1
  • Urogenital: kidneys1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
AlkaloidsUnspecifiedSolvent extractionLC-QTOF-MSResolve DOI
AlkaloidsRoots and other underground partsSolvent extraction≥ 0.02 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
AlkaloidsRoots and other underground partsSolvent extraction≤ 0.03 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
BerberineRoots and other underground partsSolvent extraction≥ 48.93 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
BerberineRoots and other underground partsSolvent extraction≤ 51.71 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
BerberineUnspecifiedSolvent extraction7.18 Milligram/gramHPLC-UVResolve DOI
BerberrubineRoots and other underground partsSolvent extraction≤ 2.08 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
BerberrubineRoots and other underground partsSolvent extraction≥ 1.96 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
ColumbamineRoots and other underground partsSolvent extraction≤ 22.48 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
ColumbamineRoots and other underground partsSolvent extraction≥ 22.37 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
CoptisineRoots and other underground partsSolvent extraction≤ 11.99 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
CoptisineUnspecifiedSolvent extraction1.95 Milligram/gramHPLC-UVResolve DOI
CoptisineRoots and other underground partsSolvent extraction≥ 11.34 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
EpiberberineRoots and other underground partsSolvent extraction≤ 10.72 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
EpiberberineRoots and other underground partsSolvent extraction≥ 10.26 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
JatrorrhizineUnspecifiedSolvent extraction0.49 Milligram/gramHPLC-UVResolve DOI
JatrorrhizineRoots and other underground partsSolvent extraction≤ 2.81 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
JatrorrhizineRoots and other underground partsSolvent extraction≥ 2.75 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
MagnoflorineRoots and other underground partsSolvent extraction≤ 2.13 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
MagnoflorineRoots and other underground partsSolvent extraction≥ 2.09 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
NoroxyhydrastinineRoots and other underground partsSolvent extraction≤ 0.18 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
NoroxyhydrastinineRoots and other underground partsSolvent extraction≥ 0.15 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
OxyberberineRoots and other underground partsSolvent extraction≤ 0.08 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
OxyberberineRoots and other underground partsSolvent extraction≥ 0.05 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
PalmatineRoots and other underground partsSolvent extraction≤ 9.37 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
PalmatineRoots and other underground partsSolvent extraction≥ 9.05 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
PalmatineUnspecifiedSolvent extraction1.96 Milligram/gramHPLC-UVResolve DOI
BerberineUnspecifiedRaw, no heat treatmentMass Spectroscopy and hyphenated methods without chromatographyNo resolvable identifier
CoptisineUnspecifiedRaw, no heat treatmentMass Spectroscopy and hyphenated methods without chromatographyNo resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
DigestiveDigestiveFlowerSolvent extractionBacillus subtilis (as organism)In vitroResolve DOI
DigestiveDigestiveFlowerSolvent extractionSaccharomyces cerevisiae (as organism)In vitroResolve DOI
EndocrineDigestiveIn vitroResolve DOI
HepatotoxicityLiverRoots and other underground partsSolvent extractionRat (as animal)SubchronicResolve DOI
HepatotoxicityLiverRoots and other underground partsRat (as animal)SubchronicResolve DOI
NephrotoxicityUrogenital: kidneysRoots and other underground partsSolvent extractionRat (as animal)SubchronicResolve DOI
SystemicHeartRoots and other underground partsRat (as animal)SubchronicResolve DOI
SystemicDigestiveRoots and other underground partsRat (as animal)SubchronicResolve DOI

Genotoxicity testing

Outcomes of genotoxicity assays as recorded in the source. A negative assay is a result under those test conditions, not a clearance.

OutcomeEndpointTestTested organismMetabolic activationSource
Positivenot reportedRat (as animal)No dataResolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Ma, Bingxin., Tong, Jing., Zhou, Gao., Mo, Qigui., He, Jingsheng., Wang, Youwei. Coptis chinensis inflorescence ameliorates hyperglycaemia in 3T3-L1 preadipocyte and streptozotocin-induced diabetic mice . Journal of functional foods, 2016, vol. 21, p. 455-462. DOI
  2. Lee, Yong-Hoon., Kim, Duyeol., Lee, Mi Ju., Kim, Myoung Jun., Jang, Ho-Song., Park, Sun Hee., Lee, Jung-Min., Lee, Hye-Yeong., Han, Beom Seok., Son, Woo-Chan., Seok, Ji Hyeon., Lee, Jong Kwon., Jeong, Jayoung., Kang, Jin Seok., Kang, Jong-Koo. Subchronic toxicity study of Coptidis Rhizoma in rats. Journal of ethnopharmacology, 2014, vol. 152, no. 3, p. 457-463. DOI
  3. Yi, Jun., Ye, Xiaoli., Wang, Dezhen., He, Kai., Yang, Yong., Liu, Xujing., Li, Xuegang. Safety evaluation of main alkaloids from Rhizoma Coptidis. Journal of ethnopharmacology, 2013, vol. 145, no. 1, p. 303-310. DOI
  4. Huang, Ping., Qian, Xiaocui., Li, Junsong., Cui, Xiaobing., Chen, Lihua., Cai, Baochang., Tan, Shanzhong. Simultaneous Determination of 11 Alkaloids in Crude and Wine-Processed Rhizoma Coptidis by HPLC-PAD . Journal of chromatographic science, 2015, vol. 53, no. 1, p. 73-78. DOI
  5. Liu, Xi., Xing, Rongrong., Chen, Xuan., Hu, Shuang., Sheng, Xia., Bai, Xiaohong. DETERMINATION OF PROTOBERBERINE ALKALOIDS IN COPTIS CHINENSIS BY MICROEXTRACTION AND HIGH PERFORMANCE LIQUID CHROMATOGRAPHY . Analytical letters, 2014, vol. 47, no. 16, p. 2655-2664. DOI
  6. Zhou, J., Ouedraogo, M., Qu, F., Duez, P. Potential genotoxicity of traditional Chinese medicinal plants and phytochemicals: An overview. Phytotherapy Research, 2013, vol. 27, no. 12, p. 1745-1755. DOI
  7. Ge, Ai-hua., Bai, Yang., Li, Jin., Liu, Jiao., He, Jun., Liu, Er-wei., Zhang, Peng., Zhang, Bo-li., Gao, Xiu-mei., Chang, Yan-xu. An activity-integrated strategy involving ultra-high-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry and fraction collector for rapid screening and characterization of the alpha-glucosidase inhibitors in Coptis chinensis Franch. (Huanglian) . Journal of pharmaceutical and biomedical analysis, 2014, vol. 100, p. 79-87. DOI
  8. Hou, Yulan., Wu, Tingting., Liu, Yaru., Wang, Hua., Chen, Yingzhuang., Chen, Bo., Sun, Wenjian. Direct analysis of quaternary alkaloids by in situ reactive desorption corona beam ionization MS. Analyst (cambridge, united kingdom), 2014, vol. 139, no. 20, p. 5185-5191.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue